1162 related articles for article (PubMed ID: 20385190)
1. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
2. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
3. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
Netzer T
Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
[TBL] [Abstract][Full Text] [Related]
4. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
Lehmann B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
[TBL] [Abstract][Full Text] [Related]
5. [European Agency for the Evaluation of Medicinal Products: five years experience].
Sauer F
Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
[TBL] [Abstract][Full Text] [Related]
6. [The regulatory framework for complementary and alternative medicines in Europe].
Knöss W; Stolte F; Reh K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
[TBL] [Abstract][Full Text] [Related]
7. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
Vlietinck A; Pieters L; Apers S
Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
[TBL] [Abstract][Full Text] [Related]
8. The regulatory system in europe with special emphasis on allergen products.
Lorenz AR; Luttkopf D; Seitz R; Vieths S
Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
[TBL] [Abstract][Full Text] [Related]
9. European regulations relevant to the marketing and use of fish vaccines.
Lee A
Dev Biol Stand; 1997; 90():341-6. PubMed ID: 9270862
[TBL] [Abstract][Full Text] [Related]
10. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua JY; Van Geertruyden JP
Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
[TBL] [Abstract][Full Text] [Related]
11. [The network of official medicines control laboratories].
Buchheit KH; Wanko R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
[TBL] [Abstract][Full Text] [Related]
12. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
Martinac AI; Tomić S; Simicić M
Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
[TBL] [Abstract][Full Text] [Related]
13. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
14. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
Menges K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
[TBL] [Abstract][Full Text] [Related]
15. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
16. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
Enzmann H; Schneider C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
[TBL] [Abstract][Full Text] [Related]
17. [How does a new medicine reach the patient?].
Visser BJ; Korevaar DA; Mokhles MM; Vermeer-Pragt W; de Boer A; Giezen TJ
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32779914
[TBL] [Abstract][Full Text] [Related]
18. The licensing of medicines in the UK.
Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
[TBL] [Abstract][Full Text] [Related]
19. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
20. [Registration of new medicinal products in Europe].
Singer E
Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
